Association between substance abuse and long-term outcome of schizophrenia – a meta-analysis Jouko Miettunen Professor of Clinical Epidemiology University.

Slides:

Advertisements

Similar presentations

Without early (subjective) improvement by antipsychotic treatment, only low chance for remission Dieter Naber Department of Psychiatry University of Hamburg.

Advertisements

Treating Schizophrenia in Low And Middle Income (LAMI) Countries: Challenges and opportunities Treating Schizophrenia in Low And Middle Income (LAMI) Countries:

The role of substance abuse in prediction of long-term outcome of schizophrenia - systematic review and meta-analysis Jouko Miettunen

SAMH Mental Health & Alcohol Conference Transforming the concept of Dual Diagnosis to the concept of Complex Needs Dr Fraser Shaw Consultant Psychiatrist.

Temperament in Schizophrenia and Bipolar disorders – A Meta-Analysis Jouko Miettunen Department of Psychiatry, University of Oulu,

C. Andres Bedoya, PhD Behavioral Medicine Service Department of Psychiatry Massachusetts General Hospital / Harvard Medical School Factors related to high-risk.

TEMPERAMENT IN INDIVIDUALS WITH PSYCHOTIC DISORDERS BEFORE AND AFTER THE ONSET OF ILLNESS Jouko Miettunen Department of Psychiatry,

Accutane-Psychiatric Disorders A Pharmacoepidemiological Safety Assessment Robert C. Nelson, PhD RCN Associates, Inc. Annapolis, MD.

Integrated Treatment of Co-Occurring Disorders

LONGITUDINAL STUDY OF TEMPERAMENT IN INDIVIDUALS WITH PSYCHOTIC DISORDERS AND HEALTHY CONTROLS Jouko Miettunen (1), Eka Roivainen (2), Juha Veijola (1,3),

Journal Club Alcohol, Other Drugs, and Health: Current Evidence November-December 2007.

Journal Club Alcohol, Other Drugs, and Health: Current Evidence September-October 2007.

Journal Club Alcohol and Health: Current Evidence September-October 2005.

Self-Destructive Behaviors: Definitions & Rates Prof. Matthew K. Nock.

Psychiatric Comorbidity of Smoking and Nicotine Dependence: An Epidemiologic Perspective Naomi Breslau, Ph.D. Department of Epidemiology Michigan State.

Chapter 2 The Problem of Dual Diagnosis. Dual Diagnosis and Comorbidity Dual diagnosis – Describes individuals who meet diagnostic criteria for a mental.

IS CANNABIS A RISK FACTOR FOR SCHIZOPHRENIA? Jouko Miettunen Department of Public Health and Primary Care Institute of Public Health University of Cambridge.

® Introduction Substance Abuse and Use of Opioids for Low Back Pain Nabil Aounallah, Sunand Kallumadanda, MD, Sandra Burge, PhD The University of Texas.

ALCOHOL USE AND AGGRESSION IN ADOLESCENTS - A META-ANALYSIS Jouko Miettunen, Adjunct Professor Department of Psychiatry University of Oulu, Finland

Comorbidity in SLE Compared with Rheumatoid Arthritis and Non-inflammatory Disorders Frederick Wolfe 1, Kaleb Michaud 1,2, Tracy Li 3, Robert S. Katz 4.

Jouko Miettunen University of Oulu, Finland

Cannabis use and its socio- demographic correlates among in-school adolescents in Zambia Emmanuel Rudatsikira, MD, DrPH Dean & Professor School of Health.

It’s Possible to prevent social exclusion among mentally ill?: IPSE Project, " Clinical Case Management " in Schizophrenic Patients in two catchment areas.

NIDA Grants: U10DA015831, K24DA022288, U10DA020024, K23DA022297, U10DA Predictors of Outcome in the Multi-Site CTN Prescription Opioid Addiction.

SLIDE 1 of 34 IS THERE A CAUSAL RELATIONSHIP BETWEEN SUBSTANCE ABUSE AND PSYCHIATRIC ILLNESS? Dr Martin Frisher Department of Medicines Management Keele.

The relationship between substance abuse treatment and self-reported outcomes among offenders with mental health problems and substance use problems Natalie.

Background Development of Anxiety Among Depressed Veterans After Antidepressant Usage Zhiguo Li, Paul Pfeiffer, Katherine Hoggatt, Kara Zivin, Karen Downing.

Next-Generation Strategies for the Therapeutic Management of Schizophrenia Diana O. Perkins, MD, MPH Professor, Department of Psychiatry Medical Director.

Dealing with bi-directionality in mental health research: The experience of the mental health project of the MRC/UVRI E. Kinyanda 1,2 1 MRC/UVRI Uganda.

FONDE : A major new international research initiative (Marseille)

Metabolic Syndrome and Recurrence within the 21-Gene Recurrence Score Assay Risk Categories in Lymph Node Negative Breast Cancer Lakhani A et al. Proc.

1 Longitudinal associations between childhood and adolescent emotional problems, behavioral problems and substance use Jouko Miettunen, adjunct professor.

Patterns of alcohol and substance use among treatment-seeking problem gamblers Linshan Gu (Jessica), Grace Wang, Maria Bellringer, Nick Garrett 6 th National.

Comorbidity, Prevalance and Trends. General Definition of Comorbidity  Historical Origins (Feinstein, 1970)  General Definition: Two or more physical.

John McGrath Sukanta Saha Joy Welham David Chant A systematic review of the incidence of schizophrenia.

Copyright restrictions may apply Predictive Values of Psychiatric Symptoms for Internet Addiction in Adolescents: A 2-Year Prospective Study Ko C-H, Yen.

LENGTH OF FIRST HOSPITALIZATION AND OTHER PREDICTORS FOR RE-HOSPITALIZATION IN PSYCHOSES Jouko Miettunen, PhD Department of Psychiatry University of Oulu,

Impact of transient and persistent personality disturbance on the outcome of anxiety and depressive disorders Professor Peter Tyrer (Imperial College,

Do Instrumental Activities of Daily Living Predict Dementia at 1- and 2- Year Follow-Up? Findings from the Development of Screening Guidelines and Diagnostic.

A systematic review and meta-analysis of recovery from schizophrenic psychoses Erika Jääskeläinen (1), Pauliina Juola (1), John McGrath (2), Sukanta Saha.

Comorbidity, Prevalance and Trends. General Definition of Comorbidity  Historical Origins (Feinstein, 1970)  General Definition: Two or more physical.

Going back to work or to study after a first-episode psychosis : the impact of an early intervention program over 5 years Amal Abdel-Baki (1,2), Geneviève.

Recovery from schizophrenia – a meta-analysis Erika Jääskeläinen (née Lauronen) and Jouko Miettunen University of Oulu, Finland.

Relational Discord at Conclusion of Treatment Predicts Future Substance Use for Partnered Patients Wayne H. Denton, MD, PhD; Paul A. Nakonezny, PhD; Bryon.

Smoking and Mental Health Problems in Treatment-Seeking University Students Eric Heiligenstein, M.D. University of Wisconsin-Madison Health Services Stevens.

Introduction  The National Epidemiological Survey on Alcohol and Related Conditions (NESARC) is one of the largest epidemiological studies to date providing.

Familial Aggregation of Suicide Explained by Cluster B Traits: A Three-Group Family Study of Suicide Controlling for Major Depressive Disorder kongdi.

Brain diseases: Substance abuse and co-occurring disorders Mark Publicker, MD FASAM.

PHQ-9 Severity and Screening Tests Predictive of Remission Outcomes at Six Months Kurt B. Angstman, MS MD Associate Professor John M. Wilkinson Assistant.

Do abnormally low concentrations of Vitamin D during pregnancy contribute to postpartum depression? Anita Cintron-Rivera, PA-S School of PA Studies | Pacific.

Randomized Controlled CTN Trial of OROS-MPH + CBT in Adolescents with ADHD and Substance Use Disorders Paula Riggs, M.D., Theresa Winhusen, PhD., Jeff.

Date of download: 5/30/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Ten-Year Course of Borderline Personality Disorder:

BASELINE BMI DOES NOT PREDICT SIX MONTH REMISSION RATE FOR DEPRESSION MANAGED UNDER COLLABORATIVE CARE MANAGEMENT Kurt B. Angstman, MS MD Todd W. Wade,

Medication Adherence and Substance Abuse Predict 18-Month Recidivism among Mental Health Jail Diversion Program Clients Elizabeth N. Burris 1, Evan M.

Date of download: 6/9/2016 From: Antipsychotics in Adults With Schizophrenia: Comparative Effectiveness of First-Generation Versus Second-Generation Medications:

Prodromal Phases Preceding First-Major Episodes of Bipolar-I Disorder: Prediction of Later Illness Salvatore P, a,b,c Khalsa HMK, a Vazquez G, b Tohen.

©2016 MFMER | slide-1 Patient screening tools associated with prediction of depression remission at six months Kurt B. Angstman, MS MD Professor of Family.

Titel voorbeeld titel The relationship between care practice organization and quality of care in long term care facilities in Europe Background Care practice.

Amir Ahmed ElKhalifa Mufaddel MD-Sudan Medical Specialisation Board. Adjunct Lecturer, United Arab Emirates University Community Mental Health Services,

Screening for Alcohol Use and Alcohol Use Disorder in Psychiatric Inpatient Settings Michael M. Miller, MD, FASAM, FAPA National Association of Psychiatric.

Table 1. Characterization of the SCOPUS data base’s articles included in the sample Selene Cordeiro Vasconcelos et al. Psychiatrics Disorders in Crack.

©2015 MFMER | slide-1 PTSD: Worsening outcomes for comorbid depression… even with collaborative care management. Kurt B. Angstman, MS, MD Professor of.

Date of download: 9/20/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Effects of a Palliative Care Intervention on Clinical.

Volume 247, Pages (January 2017)

Sercan KARABULUT*, Lütfi İlhan YARGIÇ*

Premorbid temperament as a predictor for remission in depression

A systematic review of the relationship between substance abuse and psychotropic medication adherence: opportunities to improve outcomes for patients with.

The factorial structure of negative symptoms in medication naïve First Episode Psychosis sample Demjaha A, Galderisi S, Arango C, Rodriguez-Jimenez R,

A comparison between North and South of Europe

Copyright Notice This presentation is copyrighted by the Psychopharmacology Institute. Subscribers can download it and use it for professional use. The.

Presentation transcript:

Association between substance abuse and long-term outcome of schizophrenia – a meta-analysis Jouko Miettunen Professor of Clinical Epidemiology University of Oulu, Finland

Conflicts of interest: None

Alcohol and other substance use problems are common among individuals with schizophrenia. Many of the previous studies have focused on clinical comorbidity, not on longitudinal studies aiming to look for possible causal associations. Cannabis is a potential risk factor for schizophrenia We aimed to investigate if premorbid or early substance use predicts long-term clinical and social course in schizophrenia.

Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J. Rate of cannabis use disorders in clinical samples of patients with schizophrenia: a meta-analysis. Schizophr Bull 2010; 36: Approximately every fourth schizophrenia patient had a diagnosis of cannabis use disorders (35 studies). median current rate of cannabis use disorders was 16.0% and median lifetime rate was 27.1% higher in first-episode vs. long-term patients (current 28.6% vs. 22.0%) Approximately every fifth schizophrenia patient had a diagnosis of cannabis use disorders (60 studies). Koskinen J, Löhönen J, Koponen H, Isohanni M, Miettunen J. Prevalence of alcohol use disorders in schizophrenia - a systematic review and meta-analysis. Acta Psychiatr Scand 2009; 120:

Prevalence of cannabis use disorder

A meta-analysis including nine mainly cross-sectional studies found that substance using patients have more positive, but less negative symptoms (Talamo et al. 2006). In depressive symptoms, Potvin et al. (2007) found that substance using schizophrenia patients have more depressive symptoms, although the difference was smaller than commonly assumed. Other outcomes, such as employment or social functioning, have not been studied in systematic reviews. Substance Abuse and Outcome Potvin S, et al. Austr NZ J Psychiatry 2007; 41: 792-9; Talamo A, et al. Schizophr Res. 2006;86:251–255.

A systematic review to identify potentially relevant studies was conducted. Only studies with a follow-up period of at least two years were included. We studied following outcomes: negative, positive and total symptoms clinical remission hospitalizations social functioning employment global outcome Current data search until January 2014 Substance Abuse and Outcome

The search identified 9582 unique potentially relevant articles of which 25 studies presenting results from 30 samples met our inclusion criteria. The meta-analysis included 5 to 13 studies in each outcome category. Identification of Studies

ReferenceSample (M/F)Outcome(s) Addington and Addington 1998 (Canada) 80 (54/26) positive, negative and total symptoms (PANSS) Arndt et al (USA)131 (93/38) symptoms (SANS/SAPS), hospitalization, global outcome (GAS), social and overall functioning Blow et al (USA)682 (660/22) hospitalization, symptoms (BPRS), functioning (GAF) Bodén et al (Sweden)71 functioning (living independently, work/ studying 50%, and meeting friends) Bühler et al (Germany)46employment Caspari 1999 (Germany)53 (41/12) global outcome (GAS), hospitalization, employment, positive and negative symptoms (BPRS, AMDP) Cleghorn et al (Canada)27 (19/8)positive and negative symptoms Dubertret et al (France)181 (~118/63)positive and negative symptoms Foti et al (USA)162symptoms (SAPS, SANS), global (GAF) Haro et al (worldwide: six areas) 11078clinical and functional (social) remission

ReferenceSample(M/F)Outcome(s) Hodgins et al (UK)225 menreal life functioning Huguelet et al (Switzerland)37 (18/19)hospitalization, relapse, functioning (GAF) Jockers-Scherübl et al (Germany) 39 (23/16) positive and negative symptoms, hospitalization, global clinical outcome (CGI) Jordan et al (Canada) 159 (108/51) social functioning Juola et al. 2013, Miettunen et al (Finland) 105 (63/43)employment Kozaric-Kovacic et al (Croatia) 312 (150/162)social functioning, hospitalization, course Manrique-Garcia et al (357/0)hospitalization Marwaha et al (United Kingdom, France, Germany) 213 to 773employment (losing or getting job) Orlandi and Bersani 2001 (Italy)125 negative, positive, total symptoms, hospitalization Pencer et al (Canada)49employment/ productivity Verdoux et al (France)108 (72/36)employment Whitty et al (United Kingdom) 97 (63/34) Strauss–Carpenter Scale outcome scale (total score) Yen et al (Taiwan)118 (99/19)symptoms (PANSS)

Summary of results positive symptoms (n=7) negative symptoms (n=6) total psychotic symptoms (n=6) clinical remission (n=8) hospitalizations (n=7) social functioning (n=13) employment (n=7) global outcome (n=5) Study (-0.08, 0.07) 0.09 (-0.02, 0.21) 0.03 (-0.09, 0.15) (-0.05, 0.02) (-0.18, 0.07) (-0.06, 0.05) (-0.16, 0.04) (-0.13, 0.04) correlation (95% CI) (-0.08, 0.07) 0.09 (-0.02, 0.21) 0.03 (-0.09, 0.15) (-0.05, 0.02) (-0.18, 0.07) (-0.06, 0.05) (-0.16, 0.04) (-0.13, 0.04) correlation outcomes

Odds Ratio < 1 indicates lower likelihood of achieving remission Haro JM, et al. Cross-national clinical and functional remission rates: Worldwide Schizophrenia Outpatient Health Outcomes (W-SOHO) study. Br J Psychiatry 2011; 199:

Mullin K, Gupta P, Compton MT, Nielssen O, Harris A, Large M. Does giving up substance use work for patients with psychosis? A systematic meta-analysis. Aust N Z J Psychiatry 2012; 46: See also: Large M et al. Aust N Z J Psychiatry 2014; 48:418-32; Gupta P et al. Aust N Z J Psychiatry 2013; 47:524-37

although comorbid substance use associates with poorer outcome in schizophrenia, the early substance use has only a modest effect as a predictor of long-term outcome changes in substance use? effect of medication? alcohol vs. cannabis ? covariates? milder disease?

Tiina-Mari Paaso, BMed, Katja Kasurinen, BMed, Antti Mustonen, BMed, Eetu Oinas, BMed, Juha Käkelä, BMed, Erika Jääskeläinen, Adjunct Professor, Jouko Miettunen, Professor Center for Life Course Epidemiology and Systems Medicine and Research Unit for Clinical Neuroscience, University of Oulu, Oulu, Finland Medical Research Center Oulu, Oulu University Hospital and University of Oulu, Oulu, Finland Noora Hirvonen, MA Information studies, Faculty of Humanities, University of Oulu Homepage: